Claims for Patent: 6,309,859

Summary for Patent: 6,309,859

Title:	Method for removing N-terminal methionine
Abstract:	The present invention provides a method for chemically removing a N-terminal methionine residue selectively, specifically and efficiently from a peptide or a salt thereof having an optionally oxidized methinine residue at its N-terminal. The method reacts a peptide or a salt thereof having an optionally oxidized methinine residue at its N-terminal with an .alpha.-diketone derivative, followed by hydrolysis.
Inventor(s):	Nishimura; Osamu (Hyogo, JP), Suenaga; Masato (Hyogo, JP), Ohmae; Hiroaki (Nara, JP), Tsuji; Shinji (Hyogo, JP)
Assignee:	Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:	09/436,518
Patent Claims:	1. A method for removing an oxidized or unoxidized N-terminal methionine residue from a recombinantly produced polypeptide to form a bioactive polypeptide, comprising reacting a polypeptide, or a salt thereof, having said methionine residue at its N-terminus, with an .alpha.-diketone or a salt thereof in the presence of a transition metal ion and a base, and subjecting the obtained product to hydrolysis, and recovering the resultant product to obtain a bioactive polypeptide without its N-terminal methionine residue. 2. The method according to claim 1, wherein the bioactive polypeptide produced by gene recombination technology is selected from the group consisting of growth hormone, neutrophin-3, betacellulin, parathyroid hormone and interleukin-2. 3. The method according to claim 1, wherein the transition metal ion is a copper ion. 4. The method according to claim 1, wherein the base is a pyridine. 5. The method according to claim 1, wherein the hydrolysis is carried out using a base. 6. The method according to claim 5, wherein the base is an amine. 7. The method according to claim 5, wherein the base is (1) a diamine or (2) a thio- or seleno-semicarbazide. 8. The method according to claim 7, wherein the diamine is o-phenylenediamine. 9. The method of claim 5, wherein the base is an alkylamine. 10. The method of claim 5, wherein the base is an aromatic amine. 11. The method of claim 1, where the bioactive polypeptide is selected from the group of: growth hormone, parathyroid hormone, insulin, nerve growth factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, glial derived neurotrophic factor, neurotrophin-3, 4, or 6, central nerve growth factor, gliocyte growth factor, lung-derived neurotrophic factor, epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, transforming growth factor .alpha. or .beta. endothelial cell growth factor, tissue plasminogen activator, urokinase, protein C, thrombomodulin, bone morphogenetic protein, calcitonin, insulin-like growth hormone, interferon-.alpha., .beta. or .gamma., interleukin-1(.alpha., .beta.) to 12, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, granulocyte macrophage stimulating factor, thrombopoietin, somatomedin C, erythropoietin, PACAP, atrial natriuretic peptide, endothelin, megakaryocyte growth factor, hematopoietic stem cell growth factor, hepatocyte growth factor, motilin, immunotoxin, tumor necrosis factor, hirudine, corticotropin, angiotensin, angiotensin 2 and angiotensin 2-antagonistic peptides, angiotensin 3, bradykinin derivatives, bradykinin enhancing factor, .alpha., .beta. or .gamma.-endorphin, enkephalin, neutrophil chemotactic factor, gastrin, glucagon, growth hormone-releasing factor, kyotorphin, kallidin, gonadotropic hormone releasing hormone, mast cell degranulating peptide, melanocyte stimulating hormone, neurotensin, trypsin inhibitor, oxytocin, proinsulin C-peptide, secretin, somatostatin, thyroid-stimulating hormone releasing hormone, ubiquitin, urogastrone, vasopressin derivatives, kinin derivatives, tuftsin, somatomedin, corticotropin releasing factor, insulin-like growth factor, calcitonin gene related peptide, PTHrP, VIP, DHI, insulinotropuin, GRP, CCK-PZ, Galanin, Antrum Peptide, motilin, PPY, Pancreatic Polypeptide, PSP, pancreastatin, hCG, hCS, relaxin, serum thymic factor, thymopoietin, thymosin, Factor XIII, Factor VIII, prourokinase, SOD, Factor VIIa, antithrombin, betacellulin, and a mutein thereof.

Details for Patent 6,309,859

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2016-06-14
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2016-06-14